The negative Ca(2+) balance is involved in the stimulation of PTH secretion.
The low calcium (Ca(2+)) dialysate have been developed to diminish the risk of hypercalcemia with the administration of active vitamin D and Ca(2+) carbonate as phosphate binder. Today, increasing numbers of hemodialysis (HD) patients have been on the low Ca(2+) dialysate (Ca(2+) = 2.5 mEq/l). However, the clinical consequences of a negative calcium net-balance which may be induced by the use of low Ca dialysate are not well evaluated. In the present study, we explored the effects of low Ca(2+) dialysate on the calcium balance and the PTH secretion. Eighty one chronic HD patients (male/female: 47/34; mean age: 60.2 +/- 1.5 years; mean HD periods: 11.1 +/- 0.8 years) who had been dialyzed with 3.0 mEq/l Ca(2+) dialysate were studied. All patients were transferred to the low Ca dialysate, which actually brought about a negative net-balance in Ca (mean: -94.5 mg) and an increase in serum intact PTH levels (mean: +23.7%: p = 0.03) during a single HD session. However, no changes in serum ionized Ca(2+) were found in spite of negative Ca(2+) balance. One month after change to the low Ca(2+) dialysate (total 12 sessions in each case), serum intact PTH levels increased significantly (186.7 +/- 19.5 vs. 216.2 +/- 21.9 pg/ml: p = 0.01) in spite of the fact that no changes were found in serum ionized Ca(2+), Pi and Mg. This result indicates that the negative Ca(2+) balance during low-Ca(2+) hemodialysis-stimulated PTH secretion, which offset the decrease of serum Ca(2+); a trade-off phenomenon between negative Ca balance and PTH. This suggests that low Ca(2+) dialysate may exaggerate the progression of secondary hyperparathyroidism.
Yokoyama
Keitaro
K
Division of Nephrology and Hypertension, Jikei University School of Medicine, Tokyo, Japan. keitaro@mrj.biglobe.ne.jp
Kagami
Shino
S
Ohkido
Ichiro
I
Kato
Naohiko
N
Yamamoto
Hiroyasu
H
Shigematsu
Takashi
T
Nakayama
Masaaki
M
Fukagawa
Masafumi
M
Kawaguchi
Yoshindo
Y
Hosoya
Tatsuo
T
D002118:Calcium / Q000378:metabolism*; D015314:Dialysis Solutions / Q000009:adverse effects* / Q000737:chemistry; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000209:etiology / Q000378:metabolism*; D007676:Kidney Failure, Chronic / Q000150:complications / Q000378:metabolism* / Q000628:therapy; D008274:Magnesium / Q000097:blood; D010281:Parathyroid Hormone / Q000378:metabolism*; D010758:Phosphorus / Q000097:blood; D006435:Renal Dialysis
D015314:Dialysis Solutions; D010281:Parathyroid Hormone; D010758:Phosphorus; D008274:Magnesium; D002118:Calcium